DLL3-targeting antibodies and uses thereof

MYPI2025006824A0Undetermined Publication Date: 2021-01-11TRI INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025006824
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-07-11
Filing Date
2020-07-08
Publication Date
2021-01-11
Patent Text Reader

Abstract

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof. FIG. 1
Need to check novelty before this filing date? Find Prior Art